Vitrafy Life Sciences Ltd. · ASX:VFY
Vitrafy Life Sciences — Q3 FY2026 Earnings Presentation
15 slides from Vitrafy Life Sciences's earnings presentation, Apr 28, 2026
Slide 1: Quarterly Update Presentation Q3 FY26
For personal use only Quarterly Update Presentation Q3 FY26 28 APRIL 2026 Vitrafy Life Sciences Limited (ASX: VFY) ACN 622 720 254 vitrafy.com Strictly Private & Confidential 1
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer For personal use only This presentation is provided by Vitrafy Life Sciences Limited (ACN 622 720 254) (the Company). Eligible recipients Statements in this presentation are made only as at the date of this presentation and the information This presentation is provide
Slide 3: Important Notice and Disclaimer (cont.)
Important Notice and Disclaimer (cont.) For personal use only Not financial product advice Forward-looking statements speak only as at the date of this presentation and to the full extent Reliance should not be placed on the information or opinions contained in this presentation. permitted by law, t
Slide 4: Today's Presenters
Today’s Presenters For personal use only Brent Owens Simon Martin Managing Director and Chief Executive Officer Chief Financial Officer 4
Slide 5: The Vitrafy Ecosystem
The Vitrafy Ecosystem Vitrafy cryopreservation For personal use only ecosystem delivers customer value at the Guardion Cryopreservation Freezer solution level. Unit LifeChain Software Orchestration Platform One Solution, Multiple Vitrafy Thawing Units Vitrafy Smart Consumables Go-to-Market Applicati
Slide 6: Q3 FY2026 – Key Highlights
Q3 FY2026 – Key Highlights For personal use only US Military Phase II No-Wash Solution IMV Collaboration • USAISR platelet program completed. • Vitrafy's no-wash protocol delivered • Work program commenced in France with • High-quality post-thaw outcomes results far exceeding the current global anim
Slide 7: Go-to-Market Strategies and Catalysts
Go-to-Market Strategies and Catalysts For personal use only Animal Reproduction Blood Cell & Gene Therapy ▪ Technology obsolescence ▪ Standardisation ▪ Global Scale Growth Catalysts ▪ Structural supply shortages ▪ Consistency ▪ Critical for food availability ▪ Sovereign supply capability ▪ Cost of m
Slide 8: Blood & Blood Products: Military
Blood & Blood Products: Military Phase II testing completed – very promising results with potential to expand the opportunity in blood. For personal use only Regulatory Standard Replication • Phase II confirmed replication of current regulatory standard results from prior Phase I studies — demonstra
Slide 9: Blood & Blood Products — U.S. Civilian Market Opportunity
Blood & Blood Products — U.S. Civilian Market Opportunity The U.S Military platelets is translating to significant civilian blood market interest. ~900 ~72% ~13.6m ~8,000 For personal use only U.S. civilian blood collection sites operated by Top 10 networks units of whole blood & RBCs points in the
Slide 10: Cell and Gene Therapies (CGT) Highlights
Cell and Gene Therapies (CGT) Highlights Guardion launch driving CGT engagement and strengthening validation. For personal use only Industry Showcase Success • Vitrafy's first-ever industry showcase at a leading global CGT conference — generating meaningful partner and customer interest across the C
Slide 11: Animal health commercialisation highlights
Animal health commercialisation highlights IMV collaboration commenced and progressing in-line with plan. Program Delivery Commenced For personal use only • Device shipment and program development activities with IMV successfully completed. Personnel, hardware and software deployed to support the te
Slide 12: Product Development Highlights
Product Development Highlights Four additional devices for IMV and United States for customer demos and commercial deployment. Guardion Device Build Schedule Fleet Deployment 4 2 For personal use only 12 30 Cumulative Device Builds Quarterly Device Builds 10 25 8 20 6 15 Guardion units units install
Slide 13: Product Development – Regulatory Approval
Product Development – Regulatory Approval Progressing FDA approval to unlock U.S. clinical markets and enable scalable commercial deployment. For personal use only Regulatory Standard Replication • Phase II confirmed replication of current regulatory standard results from prior Phase I studies — dem
Slide 14: Financial Highlights – Q3 FY2026
Financial Highlights – Q3 FY2026 $18.5m $0.9m Financial Highlights For personal use only Cash & term Industry Growth Program deposits at end of Q3 grant receipt in Q3 Revenue Inflows Forecast • Increasing service revenues from IMV, aquaculture contracts, Industry Growth Program grant and interest in
Slide 15: Upcoming Milestones
Upcoming Milestones Key value inflection points for the remainder of FY2026 and into H1 FY2027. 1 Opportunity Conversion • Converting USAISR Phase II success into commercial engagements across civilian and For personal use only Q4 FY2026 military blood networks in the U.S. 2 IMV Phase 1 Testing • Co
Vitrafy Life Sciences — Q3 FY2026 Earnings Presentation on 6ix